company background image
APLI logo

Appili Therapeutics TSX:APLI Stock Report

Last Price

CA$0.035

Market Cap

CA$4.2m

7D

-12.5%

1Y

0%

Updated

24 Dec, 2024

Data

Company Financials

APLI Stock Overview

A biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. More details

APLI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Appili Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Appili Therapeutics
Historical stock prices
Current Share PriceCA$0.035
52 Week HighCA$0.06
52 Week LowCA$0.025
Beta0.95
1 Month Change0%
3 Month Change16.67%
1 Year Change0%
3 Year Change-71.54%
5 Year Change-95.33%
Change since IPO-95.63%

Recent News & Updates

Recent updates

Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

Mar 24
Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

Appili Therapeutics Inc.'s (TSE:APLI) Shift From Loss To Profit

Dec 09
Appili Therapeutics Inc.'s (TSE:APLI) Shift From Loss To Profit

Shareholder Returns

APLICA PharmaceuticalsCA Market
7D-12.5%1.7%-1.4%
1Y0%-27.5%15.9%

Return vs Industry: APLI exceeded the Canadian Pharmaceuticals industry which returned -27.5% over the past year.

Return vs Market: APLI underperformed the Canadian Market which returned 15.9% over the past year.

Price Volatility

Is APLI's price volatile compared to industry and market?
APLI volatility
APLI Average Weekly Movement22.7%
Pharmaceuticals Industry Average Movement12.0%
Market Average Movement8.2%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market2.9%

Stable Share Price: APLI's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: APLI's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
20159Don Cillaappilitherapeutics.com

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Appili Therapeutics Inc. Fundamentals Summary

How do Appili Therapeutics's earnings and revenue compare to its market cap?
APLI fundamental statistics
Market capCA$4.24m
Earnings (TTM)-CA$3.58m
Revenue (TTM)CA$494.78k

8.6x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APLI income statement (TTM)
RevenueCA$494.78k
Cost of RevenueCA$0
Gross ProfitCA$494.78k
Other ExpensesCA$4.08m
Earnings-CA$3.58m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.03
Gross Margin100.00%
Net Profit Margin-724.40%
Debt/Equity Ratio-79.5%

How did APLI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:52
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Appili Therapeutics Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chelsea StellickiA Capital Markets
Douglas LoeLeede Jones Gable Inc
Andre UddinResearch Capital Corporation